Health Condition 1: K040- Pulpitis
Conditions
Interventions
Intervention1: diclofenac sodium: zuventus healthcare Ltd, analgesic transdermal patches 100mg one patch per day for two days
Intervention2: ketoprofen: zuventus healthcare Ltd, analgesic transdermal
Sponsors
DR PRIYA PORWAL
Eligibility
Inclusion criteria
Inclusion criteria: Patients complaining of pain in anterior or single-rooted premolar teeth of either jaw and diagnosed as symptomatic irreversible pulpitis with or without apical periodontitis having pre operative moderate to severe pain indicated for single visit endodontics will be included in the study. A written informed consent will be taken from all the patients and only those patients ready to sign the consent letter will be included in the study
Exclusion criteria
Exclusion criteria: 1. Patients with known hypersensitivity against ketoprofen or diclofenac sodium will be excluded from the study. 2. patients with history of allergic reactions such as bronchospasm, shock, urticarial, etc., following the use of non-steroidal anti-inflammatory drugs (NSAIDs) will be excluded from the study. 3. Patients with high blood pressure and cardiac conditions will be excluded from the study. 4. Patients with sinus drainage, pus discharge, acute or chronic apical abscess will be excluded from the study. 5. Intentional RCT, fractured tooth having cracks or resorption will be excluded from the study. 6. Patients with active stomach or duodenal ulceration within the last 6 months will be excluded from the study. 7. Patients undergoing treatment with other NSAIDs or corticosteroids during the study period will be excluded from the study. 8. Patients with developmental anomalies, congenital defects, pathology or open apex, with presence of anatomical obstacles such as calcifications in the canals or any anticipated procedural difficulties related to study teeth will be excluded from the study. 9. Pregnant and lactating women will be excluded from the study. 10. Patients who have taken NSAIDS or antibiotics within 24 hrs before administration of study drug will be excluded from the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| as a outcome of the study, postoperative pain control will be assessed at 4hours, 8hours, 24hours and 48hours after the treatmentTimepoint: 4hours, 8hours, 24hours and 48hours | — |
Secondary
| Measure | Time frame |
|---|---|
| as a secondary outcome of the study adverse effects of transdermal pain relieving patches and oral analgesics will be assessed during the course of the study i.e., 48hTimepoint: 48 hours | — |
Countries
India
Contacts
Public ContactDr Priya Porwal
K. M. Shah dental college and hospital
Outcome results
None listed